WallStreetZenWallStreetZen

NASDAQ: VIVS
Vivosim Labs Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their VIVS stock forecasts and price targets.

Forecast return on equity

Is VIVS forecast to generate an efficient return?

Company
-52.11%
Industry
4.3%
Market
137.07%
VIVS's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is VIVS forecast to generate an efficient return on assets?

Company
-33.25%
Industry
-10.42%
VIVS is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

VIVS earnings per share forecast

What is VIVS's earnings per share in the next 1 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$0.89-150.71%

VIVS revenue forecast

What is VIVS's revenue in the next 1 years based on estimates from 3 analysts?

Avg 1 year Forecast
$236.6k+66.65%
VIVS's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

VIVS revenue growth forecast

How is VIVS forecast to perform vs Biotechnology companies and vs the US market?

Company
66.65%
Industry
31.46%
Market
184.56%
VIVS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
VIVS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

VIVS vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
VIVS$1.43N/AN/A
GLMD$0.57N/AN/A
SNGX$0.35N/AN/A
XRTX$2.86N/AN/A
AZTR$0.25N/AN/A
View Top Biotech Stocks

Vivosim Labs Stock Forecast FAQ

What is VIVS's earnings growth forecast for 2027-2027?

(NASDAQ: VIVS) Vivosim Labs's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 19.68%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 1,435.18%.

Vivosim Labs's earnings in 2026 is -$1,227,000.

In 2027, VIVS is forecast to generate -$2,314,305 in earnings, with the lowest earnings forecast at -$2,223,548 and the highest earnings forecast at -$2,382,373.

If you're new to stock investing, here's how to buy Vivosim Labs stock.

What is VIVS's revenue growth forecast for 2027-2027?

(NASDAQ: VIVS) Vivosim Labs's forecast annual revenue growth rate of 66.65% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.46%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 184.56%.

Vivosim Labs's revenue in 2026 is $142,000.

In 2027, VIVS is forecast to generate $617,148 in revenue, with the lowest revenue forecast at $592,946 and the highest revenue forecast at $635,300.

What is VIVS's forecast return on assets (ROA) for 2027-2027?

(NASDAQ: VIVS) forecast ROA is -33.25%, which is lower than the forecast US Biotechnology industry average of -10.42%.

What is VIVS's Earnings Per Share (EPS) forecast for 2027-2027?

(NASDAQ: VIVS) Vivosim Labs's current Earnings Per Share (EPS) is $1.75. In 2027, VIVS's EPS is forecast to hit -$0.89 (min: -$0.85, max: -$0.91).

What is VIVS's forecast return on equity (ROE) for 2027-2027?

(NASDAQ: VIVS) forecast ROE is -52.11%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.